Suvaxyn PRRS MLV
ATC code
Species
Pigs (pigs for fattening, gilts and sows)
Indications
For active immunisation of clinically healthy pigs from 1 day of age in a porcine respiratory and reproductive syndrome (PRRS) virus contaminated environment, to reduce viraemia and nasal shedding caused by infection with European strains of PRRS virus (genotype 1).
Onset of immunity: 21 days
Duration of immunity: 26 weeks
Fattening pigs:
In addition, intramuscular vaccination of seronegative 1-day-old piglets was demonstrated to reduce lung lesions against challenge administered at 26 weeks post vaccination. Intramuscular vaccination of seronegative 2-week-old piglets was demonstrated to reduce lung lesions and oral shedding against challenge administered at 28 days and at 16 weeks post-vaccination.
Additionally, nasal vaccination of seronegative 3-day-old piglets reduced viraemia, nasal shedding and lung lesions against challenge administered at 21 days postvaccination. Nasal vaccination of seropositive 3-day-old piglets reduced viraemia, nasal shedding and lung lesions against challenge administered 10 weeks postvaccination.
Gilts and sows:
In addition, pre-pregnancy vaccination of clinically healthy gilts and sows, non-PRRS virus-naïve (i.e. either previously immunised against PRRS virus via vaccination or exposed to PRRS virus via field infection) or PRRS virus-naïve, was demonstrated to reduce the transplacental infection caused by PRRS virus during the last third of pregnancy, and to reduce the associated negative impact on reproductive performance (reduction of the occurrence of stillbirths, of piglet viraemia at birth and at weaning, of lung lesions and of viral load in lungs in piglets at weaning).
Dose to be administered and administration route
Method of administration:
Immunisation must be carried out by intramuscular or nasal administration.
Reconstitute the lyophilisate with the supplied solvent. In cases where the vials containing the solvent and the lyophilisate are stored separately, verify prior to reconstituting the lyophilisate that the lot number mentioned on the vial containing the solvent is identical to the lot number mentioned on the vial containing the lyophilisate. Transfer approximately 5 ml of solvent to the vial containing the lyophilisate and ensure complete reconstitution. Transfer back the reconstituted solution into the solvent vial (containing the remaining solvent): 25 doses are reconstituted into 50 ml solvent, 50 doses are reconstituted into 100 ml solvent, and 125 doses are reconstituted into 250 ml solvent.
Dosage:
Intramuscular injection: 2 ml in the neck.
Nasal administration: 2 ml administered as 1 ml in each nostril.
Vaccination schedule:
Pigs for fattening from 1 day of age onwards:
A single dose of 2 ml is given to pigs via intramuscular administration.
Pigs for fattening from 3 days of age onwards:
A single dose of 2 ml is given to pigs via intramuscular administration, or a single dose of 2 ml is given to pigs via nasal route by administering 1 ml in each nostril using a sterile syringe not connected to a needle.
Gilts and sows:
A single dose of 2 ml is given intramuscularly prior to introduction into the sow herd, approximately 4 weeks prior to breeding. A single booster dose is given every 6 months.
Use sterile syringes and needles.
The use of a multi-dosing syringe is recommended. Use vaccination devices according to the manufacturer’s instructions. Needles for administration should be appropriate for the size of the pig.
Adverse reactions
Pigs for fattening
|
Very common (>1 animal / 10 animals treated): |
Elevated temperature1 |
|
|
Common (1 to 10 animals / 100 animals treated): |
Injection site swelling2 |
|
|
Uncommon (1 to 10 animals / 1,000 animals treated): |
Anaphylactic-type reactions (e.g. vomiting, tremors and/or mild depression)3 |
|
|
Very common (>1 animal / 10 animals treated): |
Elevated temperature1 Injection site swelling2 |
|
1Transient; observed 4 hours post vaccination. On average 0.2 °C and up to 1.0 °C individually.
2Less than0.5 cm in diameter; resolves spontaneously within 5 days without treatment.
PRRS virus-naïve gilts and sows in the first half of gestation
|
Very common (>1 animal / 10 animals treated): |
Elevated temperature1 Injection site swelling2 |
1Transient; observed 4 hours post vaccination. On average 0.8 °C and up to 1.0 °C individually.
2Less than 1.4 cm in diameter; resolves spontaneously within 9 days without treatment.
Non-PRRS virus-naïve gilts and sows in the second half of gestation
|
Very common (>1 animal / 10 animals treated): |
Elevated temperature1 Injection site swelling2 |
1Transient; observed 4 hours post vaccination. On average 0.4 °C and up to 0.6 °C individually.
2Less than 5 cm in diameter; resolves spontaneously within 32 days without treatment.
Lactating sows:
|
Very common (>1 animal / 10 animals treated): |
Elevated temperature1 Decreased appetite2 Injection site swelling3 |
1Transient, up to 2.25 ºC. Observed 3 days post vaccination; resolves spontaneously within 2 days without treatment.
2Transient, observed 1 - 4 days post vaccination and resolves spontaneously within 3 days without treatment.
3 Up to 11 cm in diameter. Transient; resolves spontaneously within 3 days without treatment.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See also section 16 of the package leaflet for contact details.
TRUSTED SOURCE
